EN | TR
E-ISSN: 3061-9947
The Tolerability of in the Adjuvant Treatment of Breast Cancer Comprising Sequential Anthracycline and Taxane Treatment: Single Center Experience
PDF
Cite
Share
Request
Original Article
VOLUME: 47 ISSUE: 2
P: 8-15
2014

The Tolerability of in the Adjuvant Treatment of Breast Cancer Comprising Sequential Anthracycline and Taxane Treatment: Single Center Experience

Acta Haematol Oncol Turc 2014;47(2):8-15
DOI: 10.5505/aot.2014.43534
Ayşe Demirci
Umut Demirci
Uğur Coşkun
Hacer Demir
Efnan Algın
Fatma Başal
Deniz Yamaç
1. Ankara Oncology Training And Research Hospital, Department Of Medical Oncology, Ankara, Turkey
2. Gazi University Medical Faculty, Department Of Medical Oncology, Ankara, Turkey
3. Ankara Numune Training And Research Hospital, Department Of Medical Oncology, Ankara, Turkey
4. Ankara Güven Hospital, Ankara, Turkey
5.
No information available.
No information available
Received Date: 2014-07-16T03:48:11
Accepted Date: 2014-10-30T14:45:10
PDF
Cite
Share
Request

Abstract

OBJECTIVE

We studied the side effects associated with the adjuvant therapy combinations containing anthracycline-taxane which is the most frequently used recently in the breast cancer. Our goal is to demonstrate these side effects affecting patient quality of life and treatment success and to emphasize the importance of patient awareness.

METHODS

In the study, the files of one hundred patients with diagnosis of breast cancer were investigated retrospectively.

RESULTS

Sixty of the patients (60%) were premenopausal and 40 of them (40%) were postmenopausal (40%). One (%1) patient was stage I, 52 (52%) patients were stage II, 47 (47%) patients were stage III. While 31 of the patients received intensive therapy [paclitaxel (n=26, 80.7%), docetaxel (n=5,19.3%)], 69 of them received 3 weekly therapy [paclitaxel (n=10, 14.4%), docetaxel (n=59, 85.6%)]. Neuropathy, neutropenia and nail changes were found to be more frequent (32.3%, p<0,05; 67.7%, p<0.05; 22.6%, p<0.05 respectively) with the dose dense regimens and febrile neutropenia was observed more often with the 3-weekly regimens. There was no significant differences in terms of anemia, thrombocytopenia, hapatotoxicity and cardiotoxicity between two groups. Neuropathy, cardiotoxicity and nail changes were detected in all patients paclitaxel group and a significant difference was found between the group receiving docetaxel (p<0,05). The difference was not significant in terms of hepatotoxicity among patients receiving docetaxel and paclitaxel.

CONCLUSION

Febrile neutropenia was more frequent in the three-weekly treatment group and neuropathy was more frequent in the dose dense group. Neuropathy was more frequent with paclitaxel receiving patients. Moreover, it was demonstrated that the nail changes seen with docetaxel in other studies can be also seen with paclitaxel when dose intensity is increased.